EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
European Commission grants approval for Amgen's IMDYLLTRA for treatment of advanced small cell lung cancer based on Phase 3 DeLLphi-304 trial showing 40% reduction in mortality risk versus chemotherapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for IMDYLLTRA for treatment of advanced small cell lung cancer based on Phase 3 DeLLphi-304 study demonstrating 40% reduction in mortality risk versus chemotherapy
Importance:8/10
Sentiment:
0.90
OncologyRegulatory ApprovalEuropeLung CancerPhase 3
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on June 3, 2026 7:33 PM